Learning how to control HIV from African genomes Despite significant advances in treatment and access to therapy, the human immunodeficiency virus remains a global health challenge with almost 40 million…
New RNA-based therapy combats melanoma in mouse models Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells – which…
Johnson & Johnson Subsidiary to Appeal Bankruptcy Court Ruling that Deprived Talc Claimants of an Equitable and Efficient Resolution Johnson & Johnson (NYSE: JNJ) (the Company) today announced its subsidiary…
AstraZeneca appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D AstraZeneca today announced the appointment of Sharon Barr as Executive Vice President, BioPharmaceuticals R&D. Sharon will succeed Mene Pangalos, who…
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Merck (NYSE: MRK), known as MSD outside…
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and…
Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumors in DESTINY-PanTumor02 Phase II trial High-level results from the primary analysis of the ongoing DESTINY-PanTumor02…
MERCK AND MODERNA INITIATE PHASE 3 STUDY EVALUATING V940 (MRNA-4157) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR ADJUVANT TREATMENT OF PATIENTS WITH RESECTED HIGH-RISK (STAGE IIB-IV) MELANOMA Merck (NYSE: MRK), known…
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a…
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee for Medicinal Products for Human…
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile…
CVS Pharmacy introduces new universal tools collection from one+other Today, on International Self-Care Day, CVS Pharmacy® is expanding its one+other assortment with the new inclusively designed Universal Tools collection to…